SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is being discussed alongside concerns about its heavy debt load, rising borrowing costs and whether AI demand and contract backlog can support its financing needs, with HSBCs bearish assessment adding to the pressure. Traders are split between viewing the balance-sheet risks and insider selling as reasons for further downside and arguing that strong demand, the backlog and Nvidia ties make the drop a buying opportunity.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to elevated crude prices and fears that Middle East shipping or energy-infrastructure attacks could disrupt supply, while weighing possible diplomacy and Russian supply relief. The community is split between bulls focused on geopolitical risk and bears expecting the risk premium to fade, with some also warning that contract-roll effects and an extended run may amplify volatility.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is fueling a heavily bearish conversation, with traders tying its political-proxy appeal to concerns about Trumps approval and the midterms, while questioning the companys business traction. A smaller bullish contingent sees a possible trading bounce and points to the pending TAE fusion deal as a potential pivot.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rebound toward a one-year high and the $30 level is driving discussion, with traders focused on whether the move can break through resistance. Some see momentum from a defensive-sector rotation and pipeline developments ahead of earnings, while others say the stock needs stronger news to sustain a breakout.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential but also to concerns about modest symptom improvement, agitation-related side effects, and discontinuations. Traders are divided, with some viewing the move as a fading bounce and adding shorts while others point to bullish analyst commentary.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a sharp selloff across AI infrastructure and neocloud stocks as investors question whether heavy data-center spending and financing risks will generate adequate returns, with Gartners warning adding to the concern. Traders disagree on whether the pressure signals more downside or an oversold opportunity, with bulls pointing to IRENs contracted demand, power assets, and managements financing reassurances.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention for a sharp rebound after a tech-led selloff, which traders link to unconfirmed reports of potential U.S.-Iran talks and easing oil prices. The community is split between viewing the move as a bullish reversal and warning it may be a bull trap amid persistent volatility and concerns about tech and AI stocks.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A semiconductor rebound after a prolonged selloff is driving attention, with traders debating whether the move signals a durable bottom or a temporary bounce amid lingering concerns about AI spending and valuations. Chip gains are part of a broader technology recovery ahead of major tech earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers

Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million.
LENSAR (NASDAQ:LNSR) shares increased byread more...

Lensar (LNSR) Q4 2025 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Lensar (LNSR) Q1 2026 Earnings Transcript

LENSAR, Inc. (NASDAQ:LNSR) Short Interest Update

LENSAR, Inc. (NASDAQ:LNSR - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 1,016,420 shares, a growth of 42.2% from the March 15th total of 714,594 shares. Approximately 24.7% of the company's stock are short sold...

LENSAR (NASDAQ:LNSR) Upgraded at Lake Street Capital

Lake Street Capital raised LENSAR from a "hold" rating to a "buy" rating and set a $10.00 price objective for the company in a research note on Wednesday...

LENSAR Q4 Earnings Call Highlights

LENSAR (NASDAQ:LNSR) executives used the company's fourth-quarter and full-year 2025 earnings call to outline how the cataract-laser maker plans to reaccelerate growth as a standalone company...

LENSAR (NASDAQ:LNSR) Releases Earnings Results, Misses Expectations By $0.02 EPS

LENSAR (NASDAQ:LNSR - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). The firm had revenue of $16.03 million for the quarter, compared to analyst estimates of $20.30...

LENSAR Stock Plunges Alcon Scraps Merger After Prolonged Regulatory Review

Alcon cancels $356 million LENSAR merger due to regulatory delays and FTC opposition, adding pressure on shares.read more...

Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback

Equity

Lensar said that its deal with Alcon is unlikely to receive necessary regulatory approvals in the U.S. by April 23 or even by July 23. 


Alcon Ends Merger Agreement With LENSAR After FTC Opposition

(RTTNews) - Alcon Inc. (ALC) announced on Monday that it has agreed with LENSAR, Inc. (LNSR) to terminate their previously announced merger agreement...

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

LENSAR Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Lensar said in a statement that it is disappointed with the outcome and the Federal Trade Commission's intent to challenge the deal.</li><li>Alcon agreed to acquire LENSAR in March 2025 for a total potential consideration of up to $16.75 per share.</li><li>Lensar, despite the termination, will retain the $10.0 million deposit contemplated by the merger agreement, it said.</li></ul>&nbsp;Shares of LENSAR, Inc. (NSR) slumped 24% after hours on Monday after the company terminated its merger agreement with eye care company Alcon Research, LLC (ALC).The commercial-stage medical device company Lensar said on Monday that the company decided to terminate the deal after the two companies concluded that it is in the best interest of both. Lensar further added that the deal is unlikely to receive necessary regulatory approvals in the U.S. by April 23 or even by an extended deadline of July 23.Lensar said in a statement that it is disappointed with the outcome and the Federal Trade Commission's intent to challenge the deal.<h2 class="st-heading-2">The Deal That Fell Through</h2>Alcon agreed to acquire LENSAR in March 2025 for a total potential consideration of up to $16.75 per share. This included an upfront payment of $14 per share in cash and an additional non-tradeable contingent value right offering up to $2.75 per share in cash. Alcon then said that the transaction is anticipated to close in mid-to-late 2025.However, last month Lensar said that it now expects the transaction to close only by the first half of 2026 as the two companies continue to cater to the FTC’s demand for additional information pertaining to the acquisition.“...the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission’s opposition,” said Alcon CEO David J. Endicott. Lensar, however, will retain the $10.0 million deposit contemplated by the merger agreement, it said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LNSR stock stayed within the ‘bullish’ territory while sentiment around ALC remained ‘neutral’.<a href="https://stocktwits.com/symbol/LNSR">LNSR stock</a> has dropped 34% over the past 12 months while <a href="https://stocktwits.com/symbol/ALC">ALC shares</a> fell 13%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-shares-rise-as-company-begins-enrollment-in-gene-therapy-safety-enhancement-study/cZ3PezERIQd">Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Lensar said that its deal with Alcon is unlikely to receive necessary regulatory approvals in the U.S. by April 23 or even by July 23. 

Alcon Inc. - Registered Shares

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$5.78
Prev Close	$5.75
Open	$5.75
Dividend Yield	0.00%
50-Day Moving Average	$7.40
Beta	0.60
Avg. Volume	64,983.37
PE Ratio	-17.60

52-Week High	$12.94
52-Week Low	$4.95
Market Capitalization	$70.64M
EPS (Annual)	-$2.87
Price to Book	4.74
Revenue Per Employee	$389,566.67

Feed

News

Sentiment

Earnings

Fundamentals

Info

LNSR Fundamentals